TP53 and non-small cell lung carcinoma: Concomitant alterations were observed in 34.8% of cases, with <i>TP53</i> being the most common co-mutation partner.<h4>Conclusions</h4>Our real-world data confirm the feasibility and clinical value of routine NGS testing for NSCLC.